Prasurel
Tablet
Incepta Pharmaceuticals Ltd.Generic:
Prasugrel HydrochlorideWeight:
5 mgbest Price:
? 12.00Generic
Prasugrel Hydrochloride
Indications
Prasugrel is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI). Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.
Contraindications
Coadministration of Prasugrel and warfarin increases the risk of bleeding. Coadministration of Prasugrel and NSAIDs (used chronically) may increase the risk of bleeding. Prasugrel can be administered with drugs that are inducers or inhibitors of cytochrome P450 enzymes. Prasugrel can be administered with aspirin (75 mg to 325 mg per day), heparin, GPIIb/IIIa inhibitors, statins, and drugs that elevate gastric pH, including proton pump inhibitors and H2 blockers.
Side Effects
Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. Patient with a history of prior transient ischemic attack or stroke
Pregnancy And Lactation
Bleeding Thrombotic thrombocytopenic purpura Other side effects (Headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc)
Therapeutic
CABG-related bleeding: Risk increases in patients receiving Prasugrel who undergo CABG. Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death
Storage Conditions
Pediatric Use: Safety and effectiveness in pediatric patients have not been established. Geriatric Use: Patients > 75 years of age who received Prasugrel had an increased risk of fatal bleeding events (1.0%) compared to patients who received Clopidogrel (0.1%). Renal Impairment: No dosage adjustment is necessary for patients with renal impairment. There is limited experience in patients with end-stage renal disease. Hepatic Impairment: No dosage adjustment is necessary in patients with mild to moderate hepatic impairment.
Over The Counter Products
